查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938213

腸道假性阻塞治療市場－全球產業規模、佔有率、趨勢、機會及預測（依病症、診斷、治療、最終用戶、地區及競爭格局分類，2021-2031年）

Intestinal Pseudo Obstruction Treatment Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Condition, By Diagnosis, By Treatment, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腸道假性阻塞治療市場預計將從 2025 年的 210.8 億美元成長到 2031 年的 285.9 億美元，複合年成長率為 5.21%。

該市場包括旨在治療非機械性腸阻塞性腸道推進功能障礙的藥物療法、營養支持系統和外科手術。其成長主要受糖尿病和鴉片類藥物引起的腸道功能障礙等繼發性病因日益普遍以及用於恢復胃腸動力的促效劑不斷改進的推動。

市場概覽
預測期 2027-2031
市場規模：2025年 210.8億美元
市場規模：2031年 285.9億美元
複合年成長率：2026-2031年 5.21%
成長最快的細分市場 慢性的
最大的市場 北美洲

然而，限制市場成長的主要障礙在於難以做出準確診斷，這往往導致治療延遲和治療錯誤。近期臨床研究結果也表明，目前對支持性治療的依賴程度較高，而非根治性治療。根據歐洲腸道功能障礙復健和移植網路2024年的一項調查，87.7%的受訪兒童患者需要長期營養支持，這凸顯了該領域長期管理治療的迫切需求。

市場促進因素

伴隨而來的慢性疾病和神經系統疾病的日益增多，顯著擴大了全球腸道假性阻塞治療市場的潛在患者群體。由於這種疾病通常是糖尿病和全身性硬化症等全身性疾病的繼發性併發症，這些合併症日益加重的全球負擔直接催生了對腸道動力管理解決方案的需求。例如，根據國際糖尿病聯盟 (IDF) 2024 年的報告，全球約有 5.89 億成年人將患有糖尿病，這使得該族群面臨次發性胃腸神經病變的巨大風險。這種流行病學上的成長需要市場做出持續的反應，因為這些慢性疾病的進展往往會導致嚴重的腸道動力障礙，從而增加對藥物治療和長期營養支持的需求，以解決相關的胃腸功能障礙。

同時，針對罕見運動障礙的研發策略正推動新療法的湧現。產業相關人員正加大對精準醫療和早期計劃的投入，以解決腸道假性阻塞的複雜病理學，超越單純的症狀管理。這一趨勢在近期的資金籌措活動中顯而易見。根據FirstWord Pharma報道，ThirtyFiveBio於2024年7月接受643,371英鎊的津貼，用於加速開發First-in-ClassGPR35抑制劑。更廣泛的基礎設施投資也為創新提供了進一步的支持。英國研究與創新署（UKRI）表示，將於2024年9月推出的「生物醫學催化劑」競賽將為致力於開發包括罕見疾病在內的健康問題解決方案的公司提供高達1500萬英鎊的資金，以檢驗這一服務不足領域中的新型生物標的。

市場挑戰

準確診斷的困難是全球腸道假性阻塞治療市場擴張的主要障礙。由於腹脹和腹痛等症狀與機械性阻塞的症狀極為相似，臨床醫師常誤診。這種診斷上的混淆常常導致患者接受不必要的探查性手術或不恰當的治療，而非必要的藥物或營養療法。因此，目標患者群體長期未被識別或治療不當，阻礙了某些市場療法的廣泛應用。

這種普遍存在的管理不善嚴重限制了非侵入性治療的潛在商機。當醫療服務提供者無法區分假性腸阻塞和機械性腸阻塞時，就會延誤促動力藥和特殊營養補充劑的及時使用，從而降低這些產品的整體市場滲透率。這個問題十分嚴重；英國皇家外科醫學院2024年的一項服務評估顯示，僅有6.7%的急性結腸假性腸梗阻患者接受了最佳保守治療，這表明在標準治療通訊協定的適當應用方面存在嚴重不足。這種低效率不僅阻礙了市場成長，也分散了醫療資源，使其無法用於推動產業價值的長期管理策略。

市場趨勢

新型高選擇性5-HT4受體促效劑的研發正為腸假性阻塞的藥物治療領域注入新的活力，解決了傳統促動力藥物存在的安全隱患。這一趨勢的核心在於開發工程化合物，例如那羅那必利，它利用雙重作用機制刺激腸道蠕動，同時避免了非選擇性藥物相關的心血管風險。該領域的進展正在加速，從理論概念轉向旨在驗證其恢復胃腸推進功能療效的特定後期臨床試驗。隨著相關人員擴大這些臨床實驗療法的應用範圍，該領域已取得關鍵性進展。根據Renexxion Ireland Ltd.於2024年8月發布的新聞稿，擴展的IIb期臨床試驗「MOVE-IT」已在美國首次啟動，評估那羅那必利的安全性和有效性。這標誌著在檢驗此類高選擇性促效劑對更廣泛的動力障礙的療效方面邁出了關鍵一步。

同時，使用類升糖素肽-2 (GLP-2) 類似物改進的長期家庭腸外營養通訊協定，正將治療從單純的支持性護理轉變為積極的腸道復健。此策略旨在提高殘存腸道的吸收能力，並減少嚴重腸道功能障礙患者所需的腸外營養量和頻率。透過使用促進腸道適應的藥物，臨床醫生可以降低導管相關感染疾病等危及生命的風險。近期數據支持了這項治療益處。根據Ironwood Pharmaceuticals於2024年10月發布的STARS III期試驗最新結果，與安慰劑相比，阿普拉魯肽治療使每週腸外營養支持量顯著減少了25.5%，證實了新一代類似物有望從根本上改變長期管理方法。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球腸道假性阻塞治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按病情（急性與慢性）
    • 透過診斷（身體檢查、切片檢查、血液檢查、排放試驗、影像檢查、其他）
    • 依治療方法（藥物治療、手術、飲食療法、其他）
    • 按最終使用者（醫院/診所、門診護理中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美腸道假性阻塞治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲腸道假性阻塞治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區腸道假性阻塞治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東及非洲腸道假性阻塞治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲腸道假性阻塞治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球腸道假性阻塞治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Pfizer Inc.
  • Cipla Inc.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Lupin Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 8221

The Global Intestinal Pseudo Obstruction Treatment Market is projected to expand from USD 21.08 Billion in 2025 to USD 28.59 Billion by 2031, registering a CAGR of 5.21%. This market encompasses pharmacological treatments, nutritional support systems, and surgical procedures designed to manage impaired intestinal propulsion characterized by the absence of mechanical blockage. Growth is primarily fuelled by the rising detection of secondary etiologies, including diabetes and opioid-induced bowel dysfunction, alongside continuous improvements in prokinetic medications intended to reinstate gastrointestinal motility.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.08 Billion
Market Size 2031USD 28.59 Billion
CAGR 2026-20315.21%
Fastest Growing SegmentChronic
Largest MarketNorth America

Conversely, a major hurdle restricting market growth is the difficulty of establishing an accurate diagnosis, which often leads to postponed treatment and therapeutic errors. The heavy dependence on supportive measures rather than curative solutions is highlighted by recent clinical findings. According to a 2024 survey by the Network for Intestinal Failure Rehabilitation and Transplantation in Europe, 87.7% of evaluated pediatric patients necessitated permanent nutritional support, emphasizing the urgent and continuing need for long-term management therapies in this field.

Market Driver

The expanding prevalence of associated chronic and neurological diseases is substantially increasing the potential patient base for the Global Intestinal Pseudo Obstruction Treatment Market. Since this condition often arises as a secondary issue stemming from systemic illnesses like diabetes mellitus and systemic sclerosis, the growing global burden of these comorbidities creates a direct demand for motility management solutions. For example, the International Diabetes Federation reported in 2024 that roughly 589 million adults globally were living with diabetes, a population highly susceptible to secondary gastrointestinal neuropathies. This epidemiological increase demands a consistent market response, as the advancement of such chronic diseases frequently triggers severe intestinal dysmotility, fueling the need for pharmacological interventions and long-term nutritional support to handle the ensuing gastrointestinal failure.

Concurrently, a strategic emphasis on Research and Development for rare motility disorders is driving the creation of new therapeutic options. Industry stakeholders are increasingly investing in precision medicine and early-stage projects to tackle the intricate pathophysiology of intestinal pseudo-obstruction, aiming to go beyond basic symptom control. This trend is illustrated by recent funding activities; according to FirstWord Pharma, ThirtyFiveBio received a £643,371 grant in July 2024 to speed up the development of first-in-class GPR35 inhibitors for gastrointestinal conditions. This push for innovation is further backed by wider infrastructure investments; as per UK Research and Innovation, a biomedical catalyst competition introduced in September 2024 offered a share of up to £15 million to companies creating solutions for health issues, including rare diseases, validating new biologic targets for this underserved sector.

Market Challenge

The difficulty of securing an accurate diagnosis represents a significant obstacle to the expansion of the Global Intestinal Pseudo Obstruction Treatment Market. Because symptoms like abdominal distension and pain closely resemble those of mechanical obstruction, clinicians often misjudge the underlying condition. This diagnostic confusion frequently leads to patients enduring needless exploratory surgeries or receiving unsuitable treatments instead of the necessary pharmacological or nutritional therapies. As a result, the uptake of specific market treatments is hindered because the target patient group remains unidentified or is managed incorrectly for extended durations.

This pervasive mismanagement substantially restricts potential revenue opportunities for non-invasive therapeutic agents. When medical providers fail to differentiate pseudo-obstruction from mechanical blockages, the prompt use of prokinetics or specialized nutritional formulas is postponed, lowering the overall market penetration of these products. The scale of this problem is significant; a 2024 service evaluation by the Royal College of Surgeons of England found that only 6.7% of patients with acute colonic pseudo-obstruction received optimal conservative management, indicating a serious gap in the proper application of standard care protocols. Such inefficiencies not only impede market growth but also redirect healthcare resources away from the long-term management strategies that generate industry value.

Market Trends

The landscape for pharmacological treatment of intestinal pseudo-obstruction is being invigorated by the development of novel high-selectivity 5-HT4 receptor agonists, which address the safety concerns associated with earlier prokinetic drugs. This trend centers on engineering compounds such as naronapride that utilize dual-action mechanisms to stimulate enteric motility without imposing the cardiovascular risks linked to non-selective agents. Progress in this field is quickening, moving from theoretical concepts to concrete late-stage trials aimed at proving efficacy in restoring gastrointestinal propulsion. A significant milestone was reached when stakeholders broadened the scope of these investigative treatments; according to a press release from Renexxion Ireland Ltd. in August 2024 regarding the expansion of the Phase 2b MOVE-IT study, the first patient in the United States was dosed to assess the safety and efficacy of naronapride, representing a crucial move toward validating this class of highly selective agonists for wider motility disorders.

Simultaneously, the refinement of long-term home parenteral nutrition protocols is transforming treatment from merely supportive care to active intestinal rehabilitation through the use of glucagon-like peptide-2 (GLP-2) analogs. This strategy seeks to improve the absorptive capabilities of the remaining bowel, thereby decreasing the volume and frequency of parenteral support needed by patients suffering from severe intestinal failure. By utilizing agents that encourage intestinal adaptation, clinicians can mitigate life-threatening risks such as catheter-related infections. Recent data supports this therapeutic efficacy; according to an October 2024 update from Ironwood Pharmaceuticals on the Phase 3 STARS trial, apraglutide treatment led to a statistically significant 25.5% reduction in weekly parenteral support volume compared to a placebo, affirming the potential of next-generation analogs to fundamentally reshape long-term management approaches.

Key Market Players

  • Pfizer Inc.
  • Cipla Inc.
  • GlaxoSmithKline Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • Johnson & Johnson
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche AG
  • Lupin Limited

Report Scope

In this report, the Global Intestinal Pseudo Obstruction Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Intestinal Pseudo Obstruction Treatment Market, By Condition

  • Acute v/s Chronic

Intestinal Pseudo Obstruction Treatment Market, By Diagnosis

  • Physical Examination
  • Biopsy
  • Blood Test
  • Gastric Emptying Tests
  • Imaging Tests
  • Others

Intestinal Pseudo Obstruction Treatment Market, By Treatment

  • Medication
  • Surgery
  • Diet
  • Others

Intestinal Pseudo Obstruction Treatment Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Intestinal Pseudo Obstruction Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Intestinal Pseudo Obstruction Treatment Market.

Available Customizations:

Global Intestinal Pseudo Obstruction Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Intestinal Pseudo Obstruction Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Condition (Acute v/s Chronic)
    • 5.2.2. By Diagnosis (Physical Examination, Biopsy, Blood Test, Gastric Emptying Tests, Imaging Tests, Others)
    • 5.2.3. By Treatment (Medication, Surgery, Diet, Others)
    • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Intestinal Pseudo Obstruction Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Condition
    • 6.2.2. By Diagnosis
    • 6.2.3. By Treatment
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Intestinal Pseudo Obstruction Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Condition
        • 6.3.1.2.2. By Diagnosis
        • 6.3.1.2.3. By Treatment
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Intestinal Pseudo Obstruction Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Condition
        • 6.3.2.2.2. By Diagnosis
        • 6.3.2.2.3. By Treatment
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Intestinal Pseudo Obstruction Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Condition
        • 6.3.3.2.2. By Diagnosis
        • 6.3.3.2.3. By Treatment
        • 6.3.3.2.4. By End User

7. Europe Intestinal Pseudo Obstruction Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Condition
    • 7.2.2. By Diagnosis
    • 7.2.3. By Treatment
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Intestinal Pseudo Obstruction Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Condition
        • 7.3.1.2.2. By Diagnosis
        • 7.3.1.2.3. By Treatment
        • 7.3.1.2.4. By End User
    • 7.3.2. France Intestinal Pseudo Obstruction Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Condition
        • 7.3.2.2.2. By Diagnosis
        • 7.3.2.2.3. By Treatment
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Intestinal Pseudo Obstruction Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Condition
        • 7.3.3.2.2. By Diagnosis
        • 7.3.3.2.3. By Treatment
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Intestinal Pseudo Obstruction Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Condition
        • 7.3.4.2.2. By Diagnosis
        • 7.3.4.2.3. By Treatment
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Intestinal Pseudo Obstruction Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Condition
        • 7.3.5.2.2. By Diagnosis
        • 7.3.5.2.3. By Treatment
        • 7.3.5.2.4. By End User

8. Asia Pacific Intestinal Pseudo Obstruction Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Condition
    • 8.2.2. By Diagnosis
    • 8.2.3. By Treatment
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Intestinal Pseudo Obstruction Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Condition
        • 8.3.1.2.2. By Diagnosis
        • 8.3.1.2.3. By Treatment
        • 8.3.1.2.4. By End User
    • 8.3.2. India Intestinal Pseudo Obstruction Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Condition
        • 8.3.2.2.2. By Diagnosis
        • 8.3.2.2.3. By Treatment
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Intestinal Pseudo Obstruction Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Condition
        • 8.3.3.2.2. By Diagnosis
        • 8.3.3.2.3. By Treatment
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Intestinal Pseudo Obstruction Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Condition
        • 8.3.4.2.2. By Diagnosis
        • 8.3.4.2.3. By Treatment
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Intestinal Pseudo Obstruction Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Condition
        • 8.3.5.2.2. By Diagnosis
        • 8.3.5.2.3. By Treatment
        • 8.3.5.2.4. By End User

9. Middle East & Africa Intestinal Pseudo Obstruction Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Condition
    • 9.2.2. By Diagnosis
    • 9.2.3. By Treatment
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Intestinal Pseudo Obstruction Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Condition
        • 9.3.1.2.2. By Diagnosis
        • 9.3.1.2.3. By Treatment
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Intestinal Pseudo Obstruction Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Condition
        • 9.3.2.2.2. By Diagnosis
        • 9.3.2.2.3. By Treatment
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Intestinal Pseudo Obstruction Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Condition
        • 9.3.3.2.2. By Diagnosis
        • 9.3.3.2.3. By Treatment
        • 9.3.3.2.4. By End User

10. South America Intestinal Pseudo Obstruction Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Condition
    • 10.2.2. By Diagnosis
    • 10.2.3. By Treatment
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Intestinal Pseudo Obstruction Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Condition
        • 10.3.1.2.2. By Diagnosis
        • 10.3.1.2.3. By Treatment
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Intestinal Pseudo Obstruction Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Condition
        • 10.3.2.2.2. By Diagnosis
        • 10.3.2.2.3. By Treatment
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Intestinal Pseudo Obstruction Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Condition
        • 10.3.3.2.2. By Diagnosis
        • 10.3.3.2.3. By Treatment
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Intestinal Pseudo Obstruction Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cipla Inc.
  • 15.3. GlaxoSmithKline Plc.
  • 15.4. Teva Pharmaceutical Industries Ltd.
  • 15.5. Eli Lilly and Company
  • 15.6. Novartis AG
  • 15.7. Johnson & Johnson
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. F. Hoffmann-La Roche AG
  • 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer